Recent trends in praziquantel nanoformulations for helminthiasis treatment

Infections caused by parasitic flatworms impose a considerable worldwide health burden. Recently, World Health Organization launched its roadmap for neglected diseases for the period 2021 to 2030 and oral treatment with praziquantel (PZQ) in tablet form is the main drug therapy for combating these d...

Full description

Saved in:
Bibliographic Details
Published in:Expert opinion on drug delivery Vol. 19; no. 4; p. 383
Main Authors: Mengarda, Ana C, Iles, Bruno, F Longo, João Paulo, de Moraes, Josué
Format: Journal Article
Language:English
Published: England 03-04-2022
Subjects:
Online Access:Get more information
Tags: Add Tag
No Tags, Be the first to tag this record!
Abstract Infections caused by parasitic flatworms impose a considerable worldwide health burden. Recently, World Health Organization launched its roadmap for neglected diseases for the period 2021 to 2030 and oral treatment with praziquantel (PZQ) in tablet form is the main drug therapy for combating these diseases, but its use is limited by many drawbacks, including the high therapeutic dose due to the drug's low solubility and bioavailability. Among the strategies to improve PZQ performance, the use of drug nanocarriers has been cited as an interesting approach to overcome these pharmacological issues. This review focuses on the various types of nanomaterials (polymeric, lipidic, inorganic nanoparticles, and nanocrystals) which have been recently used to improve PZQ therapy. In addition, recent advances in PZQ nanoformulations, developed to overcome the barriers of the conventional drug are described. Considering the poor rate of discovery in the anthelmintic segment observed in recent decades, the effective management of existing drugs has become essential. The application of new strategies based on nanotechnology can extend the useful life of PZQ in new and more effective formulations. Pharmaceutical nanotechnology can solve the pharmacokinetic challenges characteristic of PZQ and improve its solubility and bioavailability.
AbstractList Infections caused by parasitic flatworms impose a considerable worldwide health burden. Recently, World Health Organization launched its roadmap for neglected diseases for the period 2021 to 2030 and oral treatment with praziquantel (PZQ) in tablet form is the main drug therapy for combating these diseases, but its use is limited by many drawbacks, including the high therapeutic dose due to the drug's low solubility and bioavailability. Among the strategies to improve PZQ performance, the use of drug nanocarriers has been cited as an interesting approach to overcome these pharmacological issues. This review focuses on the various types of nanomaterials (polymeric, lipidic, inorganic nanoparticles, and nanocrystals) which have been recently used to improve PZQ therapy. In addition, recent advances in PZQ nanoformulations, developed to overcome the barriers of the conventional drug are described. Considering the poor rate of discovery in the anthelmintic segment observed in recent decades, the effective management of existing drugs has become essential. The application of new strategies based on nanotechnology can extend the useful life of PZQ in new and more effective formulations. Pharmaceutical nanotechnology can solve the pharmacokinetic challenges characteristic of PZQ and improve its solubility and bioavailability.
Author de Moraes, Josué
F Longo, João Paulo
Mengarda, Ana C
Iles, Bruno
Author_xml – sequence: 1
  givenname: Ana C
  surname: Mengarda
  fullname: Mengarda, Ana C
  organization: Research Center for Neglected Diseases, Guarulhos University, Guarulhos, Brazil
– sequence: 2
  givenname: Bruno
  surname: Iles
  fullname: Iles, Bruno
  organization: Department of Genetics and Morphology, Institute of Biological Sciences, University of Brasília, Brasília, Brazil
– sequence: 3
  givenname: João Paulo
  surname: F Longo
  fullname: F Longo, João Paulo
  organization: Department of Genetics and Morphology, Institute of Biological Sciences, University of Brasília, Brasília, Brazil
– sequence: 4
  givenname: Josué
  surname: de Moraes
  fullname: de Moraes, Josué
  organization: Research Center for Neglected Diseases, Guarulhos University, Guarulhos, Brazil
BackLink https://www.ncbi.nlm.nih.gov/pubmed/35264036$$D View this record in MEDLINE/PubMed
BookMark eNo1j91Kw0AUhBdR7I8-gpIXSN1z9q-9lKJVKQii1-Vkc0JXkk3Nbi_06Y2oNzPMwHwwM3Ea-8hCXIFcgFzKG3AaDWq3QIk4igHt3ImYjr0unVmpiZil9C6lsk7CuZgog1aPaSqeXthzzEUeONapCLE4DPQVPo4UM7dFpNg3_dAdW8qhj6kYQ7Hntgsx7wOlkH6WlLuRcSHOGmoTX_75XLzd372uH8rt8-ZxfbstvbI2l9AQg3SuqcB5YytPTAqkBFh5sr6xnpErRmuwYaiXWtMSmWqGSilTI87F9S_3cKw6rneHIXQ0fO7-T-E3zo5R0Q
CitedBy_id crossref_primary_10_3923_bj_2023_1_7
crossref_primary_10_1128_spectrum_01393_23
crossref_primary_10_1128_spectrum_01807_22
crossref_primary_10_1128_aac_00114_24
crossref_primary_10_2217_nnm_2023_0027
crossref_primary_10_3390_ma16093382
crossref_primary_10_3390_pharmaceutics14102023
crossref_primary_10_1002_wnan_1852
crossref_primary_10_1007_s11356_022_23098_2
crossref_primary_10_3390_pharmaceutics15071910
crossref_primary_10_1021_acsomega_3c06111
crossref_primary_10_1021_acsnano_4c00014
crossref_primary_10_3390_nano12101683
crossref_primary_10_3762_bjnano_15_2
crossref_primary_10_2217_nnm_2022_0228
crossref_primary_10_2174_1574885518666230403111528
crossref_primary_10_3389_fphar_2022_917363
crossref_primary_10_4155_fmc_2023_0152
crossref_primary_10_1038_s41598_022_23110_2
crossref_primary_10_3389_fphar_2022_901459
crossref_primary_10_1016_j_ejmech_2023_115268
crossref_primary_10_3390_pharmaceutics15061583
ContentType Journal Article
DBID CGR
CUY
CVF
ECM
EIF
NPM
DOI 10.1080/17425247.2022.2051477
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
DatabaseTitleList MEDLINE
Database_xml – sequence: 1
  dbid: ECM
  name: MEDLINE
  url: https://search.ebscohost.com/login.aspx?direct=true&db=cmedm&site=ehost-live
  sourceTypes: Index Database
DeliveryMethod no_fulltext_linktorsrc
Discipline Pharmacy, Therapeutics, & Pharmacology
EISSN 1744-7593
ExternalDocumentID 35264036
Genre Journal Article
Review
GroupedDBID ---
00X
03L
0BK
0R~
29G
4.4
53G
5GY
AAMIU
AAOUU
AAPWH
ABBAB
ABEIZ
ABJNI
ABJYH
ABLIJ
ABLKL
ABVAX
ABXYU
ACGFS
ACIEZ
ADCVX
ADRBQ
ADTOD
AECIN
AENEX
AEOZL
AGDLA
AGMLL
AIJEM
AIRBT
AIYSM
AKBVH
ALMA_UNASSIGNED_HOLDINGS
ALQZU
BABNJ
BLEHA
CAZVN
CCCUG
CGR
CS3
CUY
CVF
DASJU
DAWQK
DKSSO
DU5
EBS
ECM
EIF
EJD
F5P
H13
HZ~
KRBQP
KSSTO
KWAYT
KYCEM
LJTGL
M44
M4Z
NPM
O9-
P2P
RNANH
TBQAZ
TDBHL
TERGH
TFDNU
TFL
TFW
TUROJ
TZHSB
V1S
~1N
ID FETCH-LOGICAL-c366t-1fae1077fb17c56bcaea3100119ca6cf6ce2ebe2652fe1d844a82eade1b335d22
IngestDate Wed Oct 16 00:41:16 EDT 2024
IsPeerReviewed true
IsScholarly true
Issue 4
Keywords nanoformulation
oral formulation
drug discovery
pediatric formulation
nanotechnology
parasitic diseases
helminthiasis
nanomaterials
schistosomiasis
Nanomedicine
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c366t-1fae1077fb17c56bcaea3100119ca6cf6ce2ebe2652fe1d844a82eade1b335d22
PMID 35264036
ParticipantIDs pubmed_primary_35264036
PublicationCentury 2000
PublicationDate 2022-04-03
PublicationDateYYYYMMDD 2022-04-03
PublicationDate_xml – month: 04
  year: 2022
  text: 2022-04-03
  day: 03
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
PublicationTitle Expert opinion on drug delivery
PublicationTitleAlternate Expert Opin Drug Deliv
PublicationYear 2022
SSID ssj0036701
Score 2.49657
SecondaryResourceType review_article
Snippet Infections caused by parasitic flatworms impose a considerable worldwide health burden. Recently, World Health Organization launched its roadmap for neglected...
SourceID pubmed
SourceType Index Database
StartPage 383
SubjectTerms Anthelmintics - chemistry
Anthelmintics - therapeutic use
Biological Availability
Helminthiasis - drug therapy
Humans
Praziquantel - pharmacology
Praziquantel - therapeutic use
Solubility
Title Recent trends in praziquantel nanoformulations for helminthiasis treatment
URI https://www.ncbi.nlm.nih.gov/pubmed/35264036
Volume 19
hasFullText
inHoldings 1
isFullTextHit
isPrint
link http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1LbxMxELYSkKpeEK9SnvKh6mW7JfZ617tHVIIAUVSJVOqt8q7tNFLqDWn20P76zqyzj4aC4MDFSuzIG3m-TMaez_MRsscim1uZZqGKMx4KyZMwF1kUxtJqxQrLRnktYvtDfj9LP47FeDBoJLi6vv9qaegDW-PN2X-wdjspdMBrsDm0YHVo_8ruEAdien_Vcl0XS3Uz-1nhCs4Dp1yJYWrVUOCQZXhh5pczt7qYKaxO0lLP7xzaY0XkVYC3q-oI0wV6WU0DbebI6-iYxMZNAXL-rNap7gj2y1paGwsdlC1mgm-lm_rUT1ln7KOypiq2n9DodJbKNMmKyuf1-0cVsMtFhot3X8a7VylEKGOvidj636yHM9FzppGXuPnFyXtWJMzFYy7kIT4JGoj8vCBMz8iLy9rKqAEgRr7Qyp9HN2pvN0NDMoRICoPto-Pmfx4r37HmTlg6en_v99kmW80cG_uWOn6ZPCaP1hsP-sEj5gkZGPeU7J_4yuXXB3TSXcS7OqD79KSraX79jHz1sKIeVnTmaB9WdBNWFN7QO7CiLayek9NP48nR53AtwxEWUZKsQmaVYSMpbc5kESd5oYzCtBBjWaGSwqKmHLgCnsTcGqZTIVTKkYfP8iiKNec75IErndkl1GQ5BE1xoSFoFQXTKF6aGpGj_gtSAF6SF36Nzhe-1sp5s3qvfjvymmx3WHtDHlr4IZu3ZHilq3e1wW4Bb09oaQ
link.rule.ids 782
linkProvider EBSCOhost
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Recent+trends+in+praziquantel+nanoformulations+for+helminthiasis+treatment&rft.jtitle=Expert+opinion+on+drug+delivery&rft.au=Mengarda%2C+Ana+C&rft.au=Iles%2C+Bruno&rft.au=F+Longo%2C+Jo%C3%A3o+Paulo&rft.au=de+Moraes%2C+Josu%C3%A9&rft.date=2022-04-03&rft.eissn=1744-7593&rft.volume=19&rft.issue=4&rft.spage=383&rft_id=info:doi/10.1080%2F17425247.2022.2051477&rft_id=info%3Apmid%2F35264036&rft_id=info%3Apmid%2F35264036&rft.externalDocID=35264036